Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

MicroSectors FANG and Innovation 3X Leveraged ETNTrade
Globus Medical Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

MicroSectors FANG and Innovation 3X Leveraged ETN vs Globus Medical Inc. Class A Common Stock — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $33.07 (market cap $2.94B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 3.5× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 20 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.

FNGUGMED
Market Cap
$2.94B$10.25B
Volume
1,823,7201,108,124
Sector
Leveraged / InverseHealth
52-Week High
$37.20$96.82
52-Week Low
$13.73$58.33
Typical Hold Time
20 Days0 Days
Enterprise Value
—$9.76B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MicroSectors FANG and Innovation 3X Leveraged ETN

FNGU, a 3X leveraged ETN tracking major tech stocks, trades at $36.69 with a slight 0.22% daily gain. Technical indicators show a bullish trend with strong moving average support, though RSI levels suggest potential overbought conditions. The ETN provides triple exposure to tech giants like Nvidia and Apple but carries significant volatility risks as highlighted by recent analysis of its 87% decline during previous market downturns.

The outlook remains tied to the performance of underlying tech stocks, offering amplified gains in bullish markets but severe losses during corrections. Key risks include leverage decay, concentration in mega-cap tech, and market volatility. Investors should weigh the potential for high returns against the substantial downside exposure inherent in leveraged products.

Globus Medical Inc. Class A Common Stock

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FNGU
100% Buy0% Sell
Avg holding period · 20 Days
GMED
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About MicroSectors FANG and Innovation 3X Leveraged ETN

FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.

Read more on FNGU →

About Globus Medical Inc. Class A Common Stock

Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.

Read more on GMED →